The new drug product facility can produce up to eight million vials annually of liquid or lyophilized bioconjugates for clinical and commercial programs.
The facility will more than triple Evonik’s Vancouver manufacturing capacity for lipid-based drug products, with production planned to begin by the end of 2029.
